MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Revvity Inc

Slēgts

SektorsVeselības aprūpe

93.39 -0.63

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

93.39

Max

93.77

Galvenie mērījumi

By Trading Economics

Ienākumi

14M

55M

Pārdošana

56M

720M

P/E

Sektora vidējais

39.557

36.442

EPS

1.18

Dividenžu ienesīgums

0.32

Peļņas marža

7.667

Darbinieki

11,000

EBITDA

22M

194M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+17.6% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.32%

3.00%

Nākamie ieņēmumi

2025. g. 27. okt.

Nākamais dividenžu datums

2025. g. 7. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-133M

11B

Iepriekšējā atvēršanas cena

94.02

Iepriekšējā slēgšanas cena

93.39

Ziņu noskaņojums

By Acuity

30%

70%

79 / 371 Rangs Healthcare

Revvity Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. okt. 18:13 UTC

Galvenie tirgus virzītāji

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

2025. g. 17. okt. 17:05 UTC

Galvenie tirgus virzītāji

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

2025. g. 17. okt. 15:03 UTC

Galvenie tirgus virzītāji

Obook Shares Sink Following Public Debut

2025. g. 17. okt. 14:41 UTC

Galvenie tirgus virzītāji

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

2025. g. 17. okt. 23:25 UTC

Iegādes, apvienošanās, pārņemšana

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

2025. g. 17. okt. 22:15 UTC

Tirgus saruna

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

2025. g. 17. okt. 21:15 UTC

Tirgus saruna

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

2025. g. 17. okt. 21:07 UTC

Tirgus saruna

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

2025. g. 17. okt. 21:07 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 17. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. okt. 20:34 UTC

Tirgus saruna

Deere Is Reaching the End of Its Downcycle -- Market Talk

2025. g. 17. okt. 20:27 UTC

Tirgus saruna

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

2025. g. 17. okt. 19:46 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. g. 17. okt. 19:45 UTC

Tirgus saruna

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

2025. g. 17. okt. 18:45 UTC

Tirgus saruna

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

2025. g. 17. okt. 17:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. okt. 17:51 UTC

Tirgus saruna

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

2025. g. 17. okt. 17:44 UTC

Tirgus saruna

EQT Seen With Long-Term Growth Opportunities -- Market Talk

2025. g. 17. okt. 17:35 UTC

Tirgus saruna

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

2025. g. 17. okt. 16:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 17. okt. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. okt. 16:14 UTC

Tirgus saruna

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

2025. g. 17. okt. 16:04 UTC

Tirgus saruna

Home Improvement Demand Is Starting to Pick Up -- Market Talk

2025. g. 17. okt. 15:58 UTC

Tirgus saruna

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

2025. g. 17. okt. 15:56 UTC

Peļņas

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

2025. g. 17. okt. 15:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 17. okt. 15:43 UTC

Tirgus saruna

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

2025. g. 17. okt. 14:58 UTC

Tirgus saruna

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

2025. g. 17. okt. 14:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. okt. 14:35 UTC

Tirgus saruna
Peļņas

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Salīdzinājums

Cenas izmaiņa

Revvity Inc Prognoze

Cenas mērķis

By TipRanks

17.6% augšup

Prognoze 12 mēnešiem

Vidējais 110.54 USD  17.6%

Augstākais 129 USD

Zemākais 99 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Revvity Inc  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

14 ratings

8

Pirkt

6

Turēt

0

Pārdot

Noskaņojums

By Acuity

79 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat